Trial Profile
A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With an Open-Label Safety Extension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Omiganan (Primary) ; Omiganan (Primary)
- Indications Rosacea
- Focus Registrational; Therapeutic Use
- Sponsors Cutanea Life Sciences
- 19 Feb 2019 Ireland was planned location as per European Clinical Trials Database.
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 23 Jan 2018 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.